1. Home
  2. IRD vs COEP Comparison

IRD vs COEP Comparison

Compare IRD & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • COEP
  • Stock Information
  • Founded
  • IRD 2018
  • COEP 2017
  • Country
  • IRD United States
  • COEP United States
  • Employees
  • IRD N/A
  • COEP N/A
  • Industry
  • IRD
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IRD
  • COEP Health Care
  • Exchange
  • IRD NYSE
  • COEP Nasdaq
  • Market Cap
  • IRD 36.0M
  • COEP 32.4M
  • IPO Year
  • IRD N/A
  • COEP N/A
  • Fundamental
  • Price
  • IRD $1.14
  • COEP $12.31
  • Analyst Decision
  • IRD Strong Buy
  • COEP
  • Analyst Count
  • IRD 1
  • COEP 0
  • Target Price
  • IRD $8.00
  • COEP N/A
  • AVG Volume (30 Days)
  • IRD 144.6K
  • COEP 121.3K
  • Earning Date
  • IRD 02-19-2025
  • COEP 03-25-2025
  • Dividend Yield
  • IRD N/A
  • COEP N/A
  • EPS Growth
  • IRD N/A
  • COEP N/A
  • EPS
  • IRD N/A
  • COEP N/A
  • Revenue
  • IRD $8,381,000.00
  • COEP N/A
  • Revenue This Year
  • IRD N/A
  • COEP N/A
  • Revenue Next Year
  • IRD $29.37
  • COEP N/A
  • P/E Ratio
  • IRD N/A
  • COEP N/A
  • Revenue Growth
  • IRD N/A
  • COEP N/A
  • 52 Week Low
  • IRD $0.81
  • COEP $2.31
  • 52 Week High
  • IRD $2.71
  • COEP $13.70
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • COEP 62.60
  • Support Level
  • IRD N/A
  • COEP $8.65
  • Resistance Level
  • IRD N/A
  • COEP $13.70
  • Average True Range (ATR)
  • IRD 0.00
  • COEP 1.89
  • MACD
  • IRD 0.00
  • COEP -0.21
  • Stochastic Oscillator
  • IRD 0.00
  • COEP 72.48

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: